Genetic testing may change treatment for this rare intestinal tumor

Share This Post

Appendic cancer is very rare, accounting for less than 1% of gastrointestinal tumors, and there is little scientific data on the disease, which means that the current guidelines for the treatment of colon cancer are recommended for patients with appendic cancer. To understand why some patients with appendix cancer respond to standard treatment for colon cancer, while others do not, the researchers performed a genetic analysis of 703 appendix cancer samples. This is by far the largest study of appendix cancer to compare the mutations present in the two cancer types.

The results of the study confirmed that genetic mutations in appendix cancer are different from those in colon cancer. TP53 and GNAS mutations are good predictors of survival in patients with appendix cancer. For rare appendix cancers, obtaining molecular maps will help determine potential treatment options because we do not have clinical trial data to guide standard treatment like other cancers. Equally important, the mutation spectrum can be used as a biomarker to distinguish high-risk patients who need intensive treatment to isolate them from low-risk patients.

Retrospective study found that appendix cancer includes five different subtypes: mucinous adenocarcinoma ( 46%), adenocarcinoma (30%), goblet cell carcinoma (12%), peritoneal pseudomyxoma (7.7%), and signet ring Cell carcinoma (5.2%). GNAS gene mutations that are rare in colon cancer are very common in appendix cancer, especially mucinous adenocarcinoma (52%) and peritoneal pseudomyxoma (72%). The median survival of patients with tumors with GNAS mutations is almost 10 years, while the median survival of patients with tumors with TP53 mutations is only three years, and the median survival of patients without these two gene mutations is 6 years.

This surprising discovery raises the question of whether patients with early-stage GNAS-mutant tumors need to be treated with chemotherapy because it may be cured by surgery alone, so more research is needed to prove it.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy